Su Chen

Su Chen Email and Phone Number

Founder and CEO @ Chengdu, CN
Chengdu, CN
Su Chen's Location
Chengdu, Sichuan, China, China
Su Chen's Contact Details
About Su Chen

A senior executive with over 30 years of experience in the Bio/Pharmaceutical industry and a track record of cross functional achievements in: product development, quality management, facility construction, clinical study, regulatory submission and compliance, cGMP manufacturing, supply chain management, and business and corporate development.

Su Chen's Current Company Details
Virogen Biotechnology Inc.

Virogen Biotechnology Inc.

Founder and CEO
Chengdu, CN
Su Chen Work Experience Details
  • Virogen Biotechnology Inc.
    Founder And Ceo
    Virogen Biotechnology Inc.
    Chengdu, Cn
  • Chengdu Virogen Biotechnology Co, Ltd.
    Founder And Ceo
    Chengdu Virogen Biotechnology Co, Ltd. Jan 2022 - Present
    Chengdu, Sichuan, China
    Set up and operated a startup biotechnology company developing innovative drugs in oncology, autoimmune diseases and infectious diseases for global markets.
  • Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
    Board Member
    Chengdu Kanghong Pharmaceutical Group Co.,Ltd. Jan 2019 - Dec 2021
  • Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
    Vice President
    Chengdu Kanghong Pharmaceutical Group Co.,Ltd. Jan 2017 - Dec 2021
    Chengdu, Sichuan, China
    • Held multiple meetings with FDA and European agencies and finalized the Conbercept (an innovative fusion protein independently developed by the company) global phase III clinical development plan. Filed INDs in 35 countries/regions and a special protocol assessment (SPA) application for one of the global protocols with FDA, and obtained all permissions.• Initiated and led two parallel multi-region double-blinded pivotal global trials for Conbercept starting in 2018. Made executive decisions to timely resolve escalated issues; Provided guidance and managed activities in regulatory submissions, CRO outsourcing, vendor management, supply chain management, change control, budget control and quality management; • Managed 2 global phase III studies. Completed the recruitment of over 2300 patients in 30 countries and reached study primary endpoint ahead of schedule. Reviewed and approved over 300 clinical trial agreements (CTA), maintained sufficient oversight and connections with study sites around the world during the Covid-19 pandemic to ensure the safety of patients and staff. • Managed the R&D group and obtained multiple Chinese ANDA, NDA and SNDA approvals for new indications and CMC change of existing products.
  • Beijing Kanghong Biopharmacetical Co.
    Ceo And Board Member
    Beijing Kanghong Biopharmacetical Co. Nov 2017 - Mar 2021
    Beijing, China
    • Negotiated with various agencies and obtained their endorsement and permits for building a new biologic manufacturing site in Beijing.• Hired and developed a new team of cross-functional professionals and managed daily activities; Completed thorough conceptual and detailed designs of the over 100,000 m2 state-of-the-art new biologics manufacturing facility; • Customized and ordered production systems from global top-notch suppliers, negotiated with and appointed contractors, established and controlled budgets, set up quality systems, and managed construction timeline. • The new facility was on schedule to start commissioning and qualification by the end of 2020 amid Covid-19 pandemic. Pending on the filing and approval of a new BLA with US FDA and EMA, this facility is positioned to launch products in the US, EU and other markets within 2-3 years.
  • Qilu Pharmaceutical Company
    Ceo, Biopharmaceutical Division
    Qilu Pharmaceutical Company Feb 2016 - Jan 2017
    Jinan, Shandong, China
    • Established corporate multi-year strategy and execution plan to grow the biopharma division and product pipeline.• Provided leadership and technical guidance to the team of 500 people in the areas of process development, quality management, engineering and regulatory filing to meet product development goals. Obtained multiple IND approvals from the Chinese FDA. • Led the stage 1 construction of a new commercial biologics manufacturing facility totaling over 150,000 m2. Provided technical guidance and made key decisions in a very fast-paced environment for plant and equipment design, GEP and GMP system development, automation system development, commissioning and validation, and product transfer. • With my leadership and effective multi-disciplinary collaborations, the new plant took slightly over one year to complete mechanical construction/installation and commissioning from groundbreaking, setting a record in the industry.
  • Chengdu Kanghong Pharmaceutical Group Co Ltd (0560556D)
    Vice President For R&D And Quality
    Chengdu Kanghong Pharmaceutical Group Co Ltd (0560556D) Mar 2015 - Jan 2016
    Chengdu, Sichuan, China
    • Managed the R&D group and pipeline development across small molecule, herbal medicine and biologic drugs. Managed quality improvement initiative across the company. • Obtained late-stage clinical IND approval from Chinese FDA and advanced multiple large-scale oncologic clinical studies.
  • Chengdu Kanghong Biotechnology Co.
    Ceo
    Chengdu Kanghong Biotechnology Co. Mar 2011 - Mar 2015
    Chengdu, Sichuan, China
    • Hired and trained a team of over 300 professionals to complete CMC development for an innovative fusion protein (Conbercept) for launching in the Chinese market. Obtained marketing approval for Conbercept with retina indication from the Chinese drug administration in November 2013 and passed GMP inspection in December 2013. Led post-market CMC change development and obtained regulatory approval in 2017.• Completed the construction and commissioning of a cell culture manufacturing facility according to the global GMP regulations at a fraction of the comparable US site cost. Managed and improved the quality system and manufacturing operations and prepared the new facility for a PAI. Enforced a corporate quality culture such that every day and every activity must remain compliant.• Set up a pharmacovigilance system to monitor post-market safety issues. Led and completed large-scale post-market safety studies to enrich the product safety profile in a real-world setting. Audited and approved material suppliers and product distributors and managed country-wide cold-chain distribution network. • Reached out to multinational companies and negotiated the potential licensing deal for the development and launching of Conbercept in foreign markets. • Organized multiple pre-IND meetings with US FDA and prepared for regulatory filings.
  • Chengdu Kanghong Biotechnology Co.
    Coo
    Chengdu Kanghong Biotechnology Co. Jun 2010 - Mar 2011
  • Chengdu Kanghong Biotechnology Co.
    Director Of Product Development And Strategic Planning
    Chengdu Kanghong Biotechnology Co. Oct 2009 - May 2010
  • Deloitte Consulting, Llp
    Strategy And Operations Senior Consultant
    Deloitte Consulting, Llp May 2008 - Jul 2009
    San Francisco, California, United States
    • Led a manufacturing network consolidation project as part of a multi-billion dollar Biotech M&A transaction. Developed a network rationalization strategy to drive immediate cost synergies. Created operational plans to transfer products across a network comprising of over 10 impacted factories. • Developed an M&A supply chain integration playbook for a major biopharmaceutical company based on the best practices and expert knowledge. • Analyzed and identified $40M in annual cost saving opportunities in the R&D division for a mid-size biotech firm. Assessed R&D projects in the portfolio and prioritized cost saving initiatives. • Set up and managed a project management office (PMO) for a cross-functional engagement with a leading biotech firm. Built a roadmap for setting up an enterprise-wide Information Management system.
  • Genentech
    Manufacturing Science Group Leader
    Genentech May 2005 - May 2008
    Vacaville, California, United States
    • Managed the manufacturing science arm for a 4-year, $750M, 8x25000L cell culture plant expansion project (CCP2) with the responsibility of ensuring timely licensure of the new facility.• Provided technical leadership in equipment design review, risk management (FMEA and CAPA), technology transfer, operations, validation, planning and regulatory compliance. • Championed efforts to shorten startup time between mechanical completion and the first successful trial run by 3-5 months representing a saving potential of $30M, as a result of proactive risk management, project prioritization, and cross-functional partnership.• Approved automation recipes and cGMP manufacturing procedures; Directed troubleshooting efforts and approved changes under the phase gate review and change control process. • Defined sub-project plans, timelines, resources, constraints and acceptance criteria; Tracked, controlled and reported project progress and risks. • Participated in department annual budget setting and managed contractor spending account. • Evaluated financial impact and operational issues associated with process improvement initiatives.• Recruited and developed a team of technical experts; Set individual SMART goals and provided ongoing performance coaching; Established a collaborative and innovative team culture.
  • Codexis
    Process Development And Manufacturing Leader
    Codexis Feb 2003 - May 2005
    Redwood City, California, United States
    • Managed a team of cross-functional experts for concurrently performing process development and manufacturing activities; Ensured that day-to-day operations in the pilot plant and manufacturing facility were quality and safety compliant.• Led performance improvement projects that resulted in an 8-fold increase in operational efficiency and a 3-fold reduction in production cost, through technical innovations and the application of proven Lean methodologies like 5S, DMAIC, SMED, Kaizen, Kepner Tregoe, and etc.• Launched three E. coli based recombinant products to business partners and exceeded project timeline, cost and quality expectations.• Developed a product supply strategy for the management team; Managed technology transfer and CMO activities.
  • Xoma
    Senior Scientist
    Xoma Aug 2002 - Jan 2003
    Berkeley, California, United States
    • Led cell culture process development and cGMP clinical manufacturing activities and enhanced both process robustness and operational efficiency.
  • Peoplesoft
    Staff Developer
    Peoplesoft Jun 2000 - Aug 2002
    Pleasanton, California, United States
    • Developed components for a web-based ERP package; Provided customer supports.
  • Chiron Corporation
    Senior Development Engineer
    Chiron Corporation Jun 1994 - Jun 2000
    Emeryville, California, United States
    • Developed, scaled up and optimized a total of seven mammalian cell culture, E. coli and yeast high-yield processes at laboratory (1-20L), pilot (20-100L) and manufacturing (500-10,000L) settings. • Developed and optimized downstream processes for extra cellular and intracellular antigens using centrifugation, cross flow filtration, and chromatography technologies.• Produced cGMP materials and led efforts in troubleshooting problems and variances encountered during manufacturing.• Prepared CMC section for regulatory filing and supported inspection preparations.• Published novel process model and developed new technologies to address issues in process optimization, automation and rapid product development.
  • The Scripps Research Institute
    Bioprocess Manager
    The Scripps Research Institute Sep 1992 - Jun 1994
    La Jolla, California, United States
    • Managed daily activities of a multi-million dollar bioprocess facility; Developed annual budget and operational plan under the direct leadership of the Chief Operating Officer. • Developed pilot-scale E. coli, yeast and sf9-based processes to produce and purify biologics for research use.

Su Chen Skills

Cross Functional Team Leadership Biotechnology Change Management Strategic Planning Validation Business Process Improvement Start Ups Gmp Technology Transfer Risk Management Lean Operations Strategy Construction Manufacturing Pharmaceutical Industry Program Management Management Change Control Capa Project Planning Life Sciences Product Development Leadership Process Improvement

Su Chen Education Details

Frequently Asked Questions about Su Chen

What company does Su Chen work for?

Su Chen works for Virogen Biotechnology Inc.

What is Su Chen's role at the current company?

Su Chen's current role is Founder and CEO.

What is Su Chen's email address?

Su Chen's email address is su****@****usa.net

What is Su Chen's direct phone number?

Su Chen's direct phone number is +151357*****

What schools did Su Chen attend?

Su Chen attended Ucla Anderson School Of Management, California State University - East Bay, The University Of Toledo.

What skills is Su Chen known for?

Su Chen has skills like Cross Functional Team Leadership, Biotechnology, Change Management, Strategic Planning, Validation, Business Process Improvement, Start Ups, Gmp, Technology Transfer, Risk Management, Lean Operations, Strategy.

Not the Su Chen you were looking for?

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.